Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 10:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Muscle Invasive Bladder Urothelial Carcinoma Clear all
Completed No phase listed Observational
View directory record Official record
Conditions
Bladder Cancer
Interventions
Not listed
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 6, 2016 · Synced May 21, 2026, 10:14 PM EDT
Terminated Not applicable Interventional
View directory record Official record
Conditions
Muscle Invasive Bladder Urothelial Carcinoma
Interventions
Daily Adaptive External Beam Radiation Therapy
Radiation
Lead sponsor
Varian, a Siemens Healthineers Company
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 20, 2026 · Synced May 21, 2026, 10:14 PM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Urothelial Carcinoma, Bladder Cancer
Interventions
Nivolumab in combination with Urelumab, Nivolumab monotherapy
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
5
States / cities
Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced May 21, 2026, 10:14 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
Interventions
Lymphadenectomy, Radical Cystectomy, Sacituzumab Govitecan
Procedure · Biological
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 26, 2026 · Synced May 21, 2026, 10:14 PM EDT
Recruiting Not applicable Interventional
View directory record Official record
Conditions
Bladder Cancer, Muscle Invasive Bladder Cancer (MIBC), Muscle Invasive Bladder Cancer Urothelial Carcinoma, Cystectomy
Interventions
Intravenous fluids, ERAS
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced May 21, 2026, 10:14 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Muscle Invasive Bladder Urothelial Carcinoma
Interventions
Enfortumab vedotin, Pembrolizumab
Drug
Lead sponsor
Matthew Galsky
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
5
States / cities
Duarte, California • Indianapolis, Indiana • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced May 21, 2026, 10:14 PM EDT
Completed No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
Non Muscle Invasive Bladder Cancer, Non-Muscle Invasive Bladder Urothelial Carcinoma
Interventions
Bladder EpiCheck
Diagnostic Test
Lead sponsor
Nucleix Ltd.
Industry
Eligibility
22 Years and older
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced May 21, 2026, 10:14 PM EDT
Active, not recruiting Phase 3 Interventional
View directory record Official record
Conditions
Stage 0 Bladder Urothelial Carcinoma, Stage 0is Bladder Urothelial Carcinoma, Stage I Bladder Urothelial Carcinoma
Interventions
BCG Solution, BCG Tokyo-172 Strain Solution, BCG Tokyo-172 Strain Vaccine, Laboratory Biomarker Analysis
Biological · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
174
States / cities
Mobile, Alabama • Gilbert, Arizona • Phoenix, Arizona + 111 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced May 21, 2026, 10:14 PM EDT
Completed Not applicable Interventional Results available
View directory record Official record
Conditions
Bladder Cancer
Interventions
therapeutic conventional surgery, therapeutic standard lymphadenectomy, therapeutic extended lymphadenectomy
Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years
Enrollment
658 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
29
States / cities
Los Angeles, California • Palo Alto, California • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2024 · Synced May 21, 2026, 10:14 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Recurrent Bladder Urothelial Carcinoma, Stage 0a Bladder Urothelial Carcinoma AJCC v6 and v7, Stage 0is Bladder Urothelial Carcinoma AJCC v6 and v7, Stage I Bladder Urothelial Carcinoma AJCC v6 and v7
Interventions
Atezolizumab
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
269
States / cities
Daphne, Alabama • Mobile, Alabama • Scottsdale, Arizona + 201 more
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced May 21, 2026, 10:14 PM EDT
Enrolling by invitation Early Phase 1 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Muscle Invasive Bladder Urothelial Carcinoma
Interventions
Implantable Micro-Device, Methotrexate, Carboplatin, Avelumab, Paclitaxel, Vinblastine, Gemcitabine/Cisplatin I, Methotrexate/Vinblastine/Doxorubicin/Cisplatin/Avelumab, Gemcitabine/Cisplatin II, Cisplatin, Nivolumab, Pembrolizumab, Gemcitabine/Carboplatin, Methotrexate/Vinblastine/Doxorubicin/Cisplatin, Gemcitabine/Cisplatin/Nivolumab, Erdafitinib, Paclitaxel/Docetaxel/Ifosfamide, Gemcitabine, Gemcitabine/Carboplatin/Nivolumab, Enfortumab, Sacituzumab
Device · Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 120 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced May 21, 2026, 10:14 PM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma Transitional Cell, Non-muscle Invasive Bladder Cancer, NMIBC
Interventions
Enfortumab vedotin
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
21
States / cities
Gilbert, Arizona • Scottsdale, Arizona • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced May 21, 2026, 10:14 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Bladder Cancer
Interventions
Pembrolizumab, Intismeran autogene, Placebo, Enfortumab Vedotin, Surgery (RC plus PLND)
Biological · Other · Procedure
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
10
States / cities
Los Angeles, California • Orlando, Florida • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced May 21, 2026, 10:14 PM EDT
Recruiting Phase 2Phase 3 Interventional
View directory record Official record
Conditions
Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma, Muscle Invasive Ureter Urothelial Carcinoma, Muscle Invasive Urethral Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma AJCC v6 and v7, Stage III Bladder Urothelial Carcinoma AJCC v6 and v7, Stage IV Bladder Urothelial Carcinoma AJCC v7
Interventions
Biospecimen Collection, cfDNA or ctDNA Measurement, Computed Tomography, Cystoscopy, Magnetic Resonance Imaging, Nivolumab, Questionnaire Administration, Relatlimab
Procedure · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
992 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
487
States / cities
Phoenix, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 367 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced May 21, 2026, 10:14 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Bladder Cancer
Interventions
induction cisplatin, induction 5-fluorouracil, induction gemcitabine, Induction BID radiation therapy, Induction QD radiation therapy, Consolidation BID radiation therapy, Consolidation QD radiation therapy, consolidation gemcitabine, consolidation 5-fluorouracil, consolidation cisplatin, radical cystectomy, Post-Induction Chemoradiotherapy Endoscopic Response Evaluation, adjuvant gemcitabine, adjuvant cisplatin
Drug · Radiation · Procedure
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2022
U.S. locations
10
States / cities
Atlanta, Georgia • Boise, Idaho • Springfield, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced May 21, 2026, 10:14 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Bladder Cancer
Interventions
bevacizumab, cisplatin, gemcitabine hydrochloride, paclitaxel, cysectomy
Biological · Drug · Procedure
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 120 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
4
States / cities
Charleston, South Carolina • Florence, South Carolina • Mt. Pleasant, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2018 · Synced May 21, 2026, 10:14 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Non-muscle Invasive Bladder Cancer, Non-Muscle Invasive Bladder Urothelial Carcinoma
Interventions
Durvalumab, Monalizumab
Drug
Lead sponsor
John Sfakianos
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
4
States / cities
Tampa, Florida • New Brunswick, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced May 21, 2026, 10:14 PM EDT
Completed Phase 3 Interventional
View directory record Official record
Conditions
Bladder Cancer, Urethral Cancer
Interventions
carboplatin, cisplatin, doxorubicin hydrochloride, methotrexate, paclitaxel, vinblastine sulfate
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
0 Years to 120 Years
Enrollment
490 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2007
U.S. locations
13
States / cities
Decatur, Georgia • Indianapolis, Indiana • Flemington, New Jersey + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced May 21, 2026, 10:14 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8, Muscle Invasive Bladder Carcinoma
Interventions
Cisplatin, Doxorubicin, Methotrexate, Pegfilgrastim, Pembrolizumab, Radical Cystectomy, Vinblastine Sulfate
Drug · Biological · Procedure
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced May 21, 2026, 10:14 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Bladder Cancer
Interventions
BCG intravesical live (TICE Bacillus Calmette-Guerin (BCG)), PANVAC
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
2
States / cities
Bethesda, Maryland • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 30, 2025 · Synced May 21, 2026, 10:14 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Bladder Cancer, Metastatic Bladder Cancer, Urothelial Carcinoma
Interventions
Atezolizumab, Gemcitabine, Cisplatin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
11
States / cities
Hartford, Connecticut • Basking Ridge, New Jersey • Middletown, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced May 21, 2026, 10:14 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Bladder Cancer, Muscle-Invasive Bladder Carcinoma
Interventions
Gemcitabine, Cisplatin, Cemiplimab, Fianlimab
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 1, 2025 · Synced May 21, 2026, 10:14 PM EDT
Completed Phase 1 Interventional Results available
View directory record Official record
Conditions
Recurrent Bladder Carcinoma, Stage 0a Bladder Urothelial Carcinoma, Stage 0is Bladder Urothelial Carcinoma, Stage I Bladder Cancer
Interventions
BCG Solution, Laboratory Biomarker Analysis, Pembrolizumab, Pharmacological Study
Biological · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced May 21, 2026, 10:14 PM EDT
Recruiting Not applicable Interventional
View directory record Official record
Conditions
Bladder Cancer, Muscle-Invasive Bladder Carcinoma, Urothelial Carcinoma, Pelvic Malignancy, Bladder Transitional Cell Carcinoma, Bladder Neoplasm
Interventions
Ureteral Stent Placement, No Ureteral Stent, Indocyanine Green with Fluorescence Imaging
Procedure · Diagnostic Test
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 85 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced May 21, 2026, 10:14 PM EDT